What IBD actually is, how Crohn's and UC differ, and what the evidence says about living well with it
Inflammatory bowel disease — IBD — is a term that covers two distinct conditions: Crohn's disease and ulcerative colitis. Both are chronic conditions characterised by ongoing inflammation of the gastrointestinal tract. Both involve periods of active disease — flares — and periods of reduced symptoms — remission. And both are real, serious conditions that can significantly affect quality of life.
IBD is not the same as irritable bowel syndrome (IBS). This is one of the most important distinctions in gastroenterology. IBS is a disorder of gut-brain interaction — symptoms without structural damage. IBD involves genuine inflammation and, over time, structural damage to the gut wall. The two conditions can produce similar symptoms, but their causes, investigations, and treatments are entirely different.
While both conditions involve gut inflammation, they differ in important ways — in where they affect the gut, how deeply the inflammation goes, and how they behave over time.
Can affect any part of the gastrointestinal tract from mouth to anus, but most commonly affects the end of the small intestine (terminal ileum) and/or the colon. Inflammation is transmural — it goes through the full thickness of the gut wall. Can cause skip lesions (patches of affected bowel separated by normal tissue). Associated with fistulae, strictures, and abscesses. Smoking worsens Crohn's disease.
Affects only the colon (large intestine) and rectum. Inflammation is mucosal — confined to the inner lining. Always starts in the rectum and extends continuously upward. Never involves the small intestine (except in rare "backwash ileitis"). Bloody diarrhoea is the hallmark symptom. Paradoxically, current smokers have a lower risk — though smoking carries far greater harms overall.
| Feature | Crohn's Disease | Ulcerative Colitis |
|---|---|---|
| Location | Anywhere: mouth to anus | Colon and rectum only |
| Distribution | Skip lesions (patchy) | Continuous from rectum |
| Depth of inflammation | Transmural (full thickness) | Mucosal (inner lining) |
| Hallmark symptom | Abdominal pain, diarrhoea, weight loss | Bloody diarrhoea, urgency |
| Perianal disease | Common (fistulae, abscesses) | Rare |
| Smoking effect | Worsens disease | Lowers risk (but not recommended) |
| Curative surgery | Not curative — can recur | Colectomy is curative |
The cause of IBD is not fully understood, but it is now well established as a complex interaction between genetic susceptibility, the immune system, the gut microbiome, and environmental triggers.
The immune system plays a central role. In IBD, the body mounts an abnormal inflammatory response against the contents of its own gut — particularly gut bacteria. In genetically susceptible individuals, environmental triggers appear to dysregulate this response, causing persistent inflammation rather than the normal controlled immune reaction.
IBD is diagnosed through a combination of clinical assessment, blood tests, stool tests, endoscopy, and imaging. Diagnosis requires specialist gastroenterology involvement — a GP cannot diagnose IBD from blood tests alone, but they play a critical role in recognising the symptoms and making an urgent or routine referral.
| Investigation | What it shows |
|---|---|
| Full blood count + CRP/ESR | Anaemia (common in IBD), elevated inflammatory markers during active disease |
| Faecal calprotectin | A stool protein released by inflamed gut — strongly differentiates IBD from IBS. Elevated in IBD, normal in IBS |
| Ileocolonoscopy with biopsies | The gold standard — visualises the colon and terminal ileum, takes tissue samples for histology |
| MRI enterography | Assesses small bowel in Crohn's disease — extent, strictures, fistulae, perianal disease |
| CT abdomen/pelvis | Used acutely for complications — obstruction, perforation, abscess |
| Coeliac serology, stool cultures | Exclude other causes of similar symptoms before confirming IBD |
Faecal calprotectin is particularly important in primary care. A normal result makes significant gut inflammation very unlikely and helps avoid unnecessary colonoscopy. An elevated result prompts urgent gastroenterology referral.
IBD treatment is guided by disease type (Crohn's vs UC), extent, severity, and the presence of complications. The principle is to use the least intensive effective treatment to achieve and maintain remission, escalating if needed. NICE guidelines NG129 (Crohn's) and NG130 (UC) provide the framework.
Mesalazine and related drugs are first-line for mild to moderate ulcerative colitis. They reduce mucosal inflammation and maintain remission. Effective for UC — less so for Crohn's disease, where they are not routinely recommended.
Prednisolone and budesonide are used to bring active flares under control. They are effective but not suitable for long-term maintenance — repeated or prolonged steroid use causes significant side effects (osteoporosis, adrenal suppression, diabetes, mood effects). The goal is always to taper and stop.
Azathioprine, mercaptopurine, and methotrexate suppress the immune response to maintain remission after a flare. They take several months to reach full effect. Require regular blood monitoring. Used when aminosalicylates alone are insufficient, or in Crohn's disease.
Anti-TNF drugs (infliximab/Remicade, adalimumab/Humira) — the most established biologics, effective in both Crohn's and UC. Vedolizumab — gut-selective biologic, good safety profile. Ustekinumab — effective in Crohn's. JAK inhibitors (tofacitinib, upadacitinib) — oral small molecules now used in moderate to severe UC and Crohn's. Therapeutic drug monitoring is used to optimise dosing.
Surgery is required in a significant proportion of IBD patients. For Crohn's disease, surgery removes the most affected segment of bowel — but does not cure the condition, and disease can recur at the surgical site. For ulcerative colitis, total colectomy (removal of the colon) is curative. An ileo-anal pouch procedure allows most patients to avoid a permanent stoma. Surgery is indicated for complications (obstruction, perforation, fistula, abscess), failure of medical therapy, or — in UC — for high-grade dysplasia or colorectal cancer.
Ng and colleagues published a landmark systematic review in The Lancet in 2017, analysing population-based studies from 43 countries. In the 21st century, IBD has become a global disease. Incidence is highest in North America, Northern Europe, and Australia — the UK has among the highest rates in the world. Critically, incidence is now accelerating in newly industrialised countries across Asia, South America, and Africa as they adopt Western lifestyles. The authors concluded that IBD prevalence in Western countries is continuing to rise as new cases accumulate in an increasingly large patient population.
Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. The Lancet 2017;390(10114):2769–2778. DOI: 10.1016/S0140-6736(17)32448-0
A 2022 study commissioned by Crohn's & Colitis UK and conducted by researchers at the University of Nottingham analysed anonymised health records from over 38 million people registered with UK general practices between 2000 and 2020. It found that over 500,000 people in the UK — 1 in every 123 — are living with Crohn's disease or ulcerative colitis. This is nearly double the previous estimate of 300,000. Prevalence was 0.44% for UC and 0.31% for Crohn's. Incidence in adolescents (aged 10–16) increased by an average of 3% per year over the study period. The study raised serious concerns about NHS capacity to manage the growing patient population.
Crohn's & Colitis UK / University of Nottingham. Epidemiology Summary: Incidence and Prevalence of IBD in the United Kingdom. 2022. Based on CPRD analysis of 38.3 million UK general practice records, 2000–2020.
NICE guideline NG129, published in 2019, provides the UK standard for Crohn's disease management across all ages. Key recommendations include: use of faecal calprotectin to support diagnosis in primary care; budesonide or prednisolone for inducing remission in mild to moderate disease; azathioprine or mercaptopurine for maintenance; biologics (anti-TNF, vedolizumab, ustekinumab) for moderate to severe disease or those who have not responded to conventional treatment; post-surgical prophylaxis to reduce recurrence; and smoking cessation as an essential component of management.
National Institute for Health and Care Excellence. Crohn's disease: management. NICE guideline NG129. Published May 2019.
NICE guideline NG130, also published in 2019, covers UC management from mild proctitis through to acute severe colitis. Key recommendations include: aminosalicylates (mesalazine) as first-line for mild to moderate UC; corticosteroids for inducing remission in moderate disease; azathioprine or mercaptopurine for maintenance; biological therapies for moderate to severe disease; and clear criteria for hospitalisation in acute severe UC (defined by the Truelove and Witts criteria). The guideline also covers surveillance colonoscopy recommendations — starting 8–10 years after diagnosis for extensive disease, with frequency determined by risk factors including disease extent, family history of colorectal cancer, and the presence of primary sclerosing cholangitis.
National Institute for Health and Care Excellence. Ulcerative colitis: management. NICE guideline NG130. Published May 2019.
The BSG published comprehensive consensus guidelines on IBD management in adults in 2019 (Gut), developed through systematic review of 88,247 publications and a Delphi process involving 81 multidisciplinary clinicians and patients. The guidelines produced 168 evidence- and expert opinion-based recommendations covering pharmacological treatment, surgery, nutrition, psychological support, pregnancy, and service delivery. A key emphasis is the importance of the IBD multidisciplinary team — gastroenterologist, IBD nurse specialist, dietitian, surgeon, and psychologist. The guidelines highlight that psychological comorbidity (anxiety and depression) is highly prevalent in IBD and should be actively assessed and treated.
Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, et al.; IBD guidelines eDelphi consensus group. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut 2019;68(suppl 3):s1–s106. DOI: 10.1136/gutjnl-2019-318484
King and colleagues published an analysis of changing IBD patterns in the UK between 2000 and 2018 in Alimentary Pharmacology & Therapeutics (2020), using a primary care database of 11.3 million individuals. They found that UC prevalence increased from 390 to 570 per 100,000 between 2000 and 2017, and Crohn's from 220 to 400 per 100,000. The study predicted IBD prevalence would reach 1.1% of the UK population by 2025. Incidence in adolescents rose by 3% per year. UC was associated with a 40% increased risk of colorectal cancer compared to controls. Both conditions carried increased all-cause mortality — Crohn's more so than UC.
King D, Reulen RC, Thomas T, Chandan JS, Thayakaran R, Subramanian A, et al. Changing patterns in the epidemiology and outcomes of inflammatory bowel disease in the United Kingdom: 2000–2018. Alimentary Pharmacology & Therapeutics 2020;51(10):922–934. DOI: 10.1111/apt.15701
Jess and colleagues published a meta-analysis in Clinical Gastroenterology and Hepatology in 2012, pooling data from eight population-based cohort studies to determine the risk of colorectal cancer (CRC) in patients with ulcerative colitis. They found that UC increases CRC risk approximately 2.4-fold compared to the general population. Risk was higher in men, in those diagnosed at a young age, and in those with extensive colitis. This remains the most widely cited population-based estimate and underpins NICE surveillance colonoscopy recommendations. A 2025 updated meta-analysis of 161,157 patients confirmed a pooled standardised incidence ratio (SIR — observed versus expected cancer cases) of 2.48, with extensive colitis carrying a risk approaching 4-fold. For Crohn's disease, a separate meta-analysis found a pooled CRC risk approximately 1.9-fold elevated, rising to 2.5-fold for colon cancer specifically.
Jess T, Rungoe C, Peyrin-Biroulet L. Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clinical Gastroenterology and Hepatology 2012;10(6):639–645. DOI: 10.1016/j.cgh.2012.01.010
IBD is a genuine, chronic, immune-mediated condition — not a functional disorder, not stress-related, not something you can resolve with diet alone. Both Crohn's disease and ulcerative colitis involve real inflammation that, without effective treatment, causes real damage. Getting the diagnosis right matters enormously, because the two conditions are managed differently.
The treatment landscape has transformed in the past two decades. Biologics have given gastroenterologists tools that didn't exist a generation ago. The goal is no longer simply symptom control — it is mucosal healing, preventing complications, and preserving the gut. Achieving that requires working with a specialist IBD team.
If you have IBD — or suspect you might — you deserve an accurate diagnosis, a structured management plan, access to specialist care, and support for the psychological as well as the physical impact of your condition. The condition is serious. The treatments work. And the conversation with your specialist matters.
This article is health education, not medical advice. It is intended to help you understand IBD and the evidence around it — not to replace a consultation with your own doctor or specialist. If you are concerned about any symptoms, that is a conversation for you to have with your GP or healthcare professional.